Keros Therapeutics, Inc.
KROS
$14.57
$0.412.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 4.21M | -187.35M | -181.57M | -168.05M | -160.30M |
| Total Depreciation and Amortization | 1.30M | 1.23M | 1.14M | 1.04M | 925.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 37.73M | 36.69M | 34.58M | 34.25M | 32.52M |
| Change in Net Operating Assets | 1.62M | -11.44M | 5.53M | -11.04M | -7.97M |
| Cash from Operations | 44.86M | -160.87M | -140.32M | -143.80M | -134.83M |
| Capital Expenditure | -1.55M | -1.93M | -2.18M | -2.35M | -2.35M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1.55M | -1.93M | -2.18M | -2.35M | -2.35M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 235.22M | 392.28M | 386.05M | 230.29M | 228.43M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -195.00K | -454.00K | -521.00K | -418.00K | -353.00K |
| Cash from Financing | 235.02M | 391.82M | 385.53M | 229.87M | 228.08M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 278.34M | 229.02M | 243.03M | 83.72M | 90.90M |